Clinical

Participants in the Risk Assessment and Management Program-Diabetes Mellitus had reduced risks of developing all-cause dementia by 28%, Alzheimer disease by 15%, vascular dementia by 39%, and other or unspecified dementia by 29%.

Camilla Levister, MS, ANP-C, CDCES, a nurse practitioner at the Icahn School of Medicine at Mount Sinai Hospital in New York, discusses how closed-loop systems benefit patients managing type 1 diabetes.

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology and chair of the Lymphoma Research Foundation’s scientific advisory board, discussed the changing lymphoma treatment landscape and highlighted potentially game changing treatments.

Catch up on this week's news at the Center on Health Equity and Access.

This retrospective analysis compared molecular testing outcomes among newly diagnosed cases of metastatic non–small cell lung cancer (mNSCLC) from 2 periods: March 2017 to May 2019 and July 2019 to March 2021.

The overall decline was mainly driven by decreased incidences of epithelial cancers in the ovaries, fallopian tubes, or peritoneum, as well as a decrease in the number of patients diagnosed with epithelial cancer, especially in advanced stages.

Dubbed the FLEX trial, the study will explore whether batoclimab will address important patient needs throughout different phases of the myasthenia gravis (MG).

A wave of drug supply chain problems would occur if the FDA pulled cough and cold medications containing the active ingredient phenylephrine from shelves; lawmakers in 19 states are considering bills allowing medically assisted death; tuberculosis awareness is lagging as state and local health departments lack the resources to keep up with prevention and control efforts.

The data also show how the economic burden of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is increasing.

This retrospective cohort study evaluated baseline demographics, clinical characteristics, and treatment patterns of US patients with asthma who newly initiated single- or multiple-inhaler triple therapy.

Experts delve into practical aspects of using elacestrant in later-line treatment of patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer, including testing for ESR1 mutations, evaluating efficacy, and monitoring for toxicity.

Circumstantial and direct evidence, including a review of twin and backtracking studies, demonstrate potential prenatal development of acute childhood leukemias.

This systemic review determined telemedicine to be as effective as in-person appointments for the follow-up of patients with atopic dermatitis (AD).

House Republicans voted to ban quality-adjusted life years (QALYs) from being used as a drug pricing metric in federal health programs; insurance executives disapproved of newly proposed 2025 Medicare Advantage (MA) rates; patients with long COVID enrolled in an online exercise program said their health improved more than people who received standard care.

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham fellowship in hematology/oncology and chair of the Lymphoma Research Foundation’s Scientific Advisory Board, discusses T-cell engager therapies in the diffuse large B-cell lymphoma (DLBCL) landscape.

Dr Haumschild drives a discussion surrounding the role of bruton kinase inhibitors for treating CLL and SLL.

Results show that wastewater surveillance was sufficiently sensitive to detect Monkeypox virus (mpox) cases in these large, pooled samples.

Continuous improvement was observed across the different domains of minimal disease activity criteria with guselkumab.

Dr Shamie shares her optimism in the advancement of Demodex Blepharitis treatment.

A review of insurance policies for Demodex blepharitis treatments, along with an analysis of the potential toxicities associated with these treatments.

Medical experts illustrate the impact of combination therapy for treatment of CLL and SLL.

Investigators observed an increase in the prevalence of Alzheimer disease in patients with diagnosed myasthenia gravis (MG), which indicates that MG is an independent risk factor for AD.

No causal association with psychiatric disorders was observed in patients with chronic obstructive pulmonary disease (COPD) without a smoking history, while ever-smokers with COPD had a greater risk of developing attention-deficit/hyperactivity disorder (ADHD).

A review of recent research into myelodysplastic syndromes (MDS) shows a range of potential therapeutic targets.

Light-to-moderate alcohol consumption seemed to provide greater protection against ischemic heart disease (IHD) mortality for individuals with higher socioeconomic status (SES) compared with those with lower SES, likely due to gaps in access to necessary care.